Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Akebia Therapeutics Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
23 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Apr 24
8-K
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
27 Mar 24
8-K
Departure of Directors or Certain Officers
15 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Departure of Directors or Certain Officers
13 Feb 24
S-8
Registration of securities for employees
30 Jan 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Entry into a Material Definitive Agreement
18 Dec 23
8-K
Other Events
21 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Nov 23
8-K
Akebia Receives FDA Acceptance of Resubmission to NDA of
25 Oct 23
8-K
Departure of Directors or Certain Officers
12 Oct 23
8-K
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
26 Sep 23
10-Q
2023 Q2
Quarterly report
28 Aug 23
10-K/A
2022 FY
Annual report (amended)
28 Aug 23
8-K
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
25 Aug 23
8-K
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing
17 Aug 23
8-K
Akebia Therapeutics Provides Update on Form 10-Q Filing
11 Aug 23
NT 10-Q
Notice of late quarterly filing
10 Aug 23
8-K
Departure of Directors or Certain Officers
1 Aug 23
8-K
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
18 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jun 23
8-K
Departure of Directors or Certain Officers
8 Jun 23
8-K
Regulation FD Disclosure
7 Jun 23
S-8
Registration of securities for employees
6 Jun 23
8-K
Other Events
2 Jun 23
8-K
Regulation FD Disclosure
31 May 23
8-K
Regulation FD Disclosure
30 May 23
8-K
Entry into a Material Definitive Agreement
25 May 23
Latest ownership filings
4
Nicole R. Hadas
14 May 24
4
Michel Dahan
14 May 24
144
Notice of proposed sale of securities
13 May 24
144
Notice of proposed sale of securities
13 May 24
4
Steven Keith Burke
9 May 24
4
Michel Dahan
1 Mar 24
4
Nicole R. Hadas
1 Mar 24
4
John P. Butler
1 Mar 24
4
Steven Keith Burke
1 Mar 24
4
Nicole R. Hadas
29 Feb 24
4
Michel Dahan
29 Feb 24
4
Steven Keith Burke
29 Feb 24
4
John P. Butler
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
144
Notice of proposed sale of securities
27 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Satter Muneer A
9 Feb 24
4
Nicholas Grund
2 Feb 24
4
Richard C Malabre
2 Feb 24
4
Michel Dahan
2 Feb 24
4
Ellen Snow
2 Feb 24
4
Nicole R. Hadas
2 Feb 24
4
John P. Butler
2 Feb 24
4
Steven Keith Burke
2 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
3
Nicholas Grund
18 Jan 24
3
Richard C Malabre
18 Jan 24
4
Ellen Snow
1 Aug 23
3
Ellen Snow
18 Jul 23
4
LEANNE M ZUMWALT
8 Jun 23
4
MICHAEL W ROGERS
8 Jun 23
4
RON FRIESON
8 Jun 23
4
Myles Wolf
8 Jun 23